8-K: NeuroPace Q3 Revenue Soars 30%, Boosts 2025 Guidance

NeuroPace, Inc. reported record third-quarter 2025 revenue of $27.4 million, a 30% increase year-over-year, and raised its full-year 2025 revenue and gross margin guidance.

Summary

• Reported record quarterly revenue of $27.4 million for Q3 2025, representing 30% growth compared to Q3 2024.
• RNS System revenue grew 31% to $22.6 million in Q3 2025 compared to Q3 2024.
• Achieved a strong gross margin of 77.4% in Q3 2025, up from 73.2% in Q3 2024.
• Net loss for Q3 2025 was ($3.5) million, an improvement from ($5.5) million in Q3 2024.
• Increased full-year 2025 revenue guidance to between $97 million and $98 million, representing 21% 23% growth over 2024.
• Increased full-year 2025 gross margin guidance to between 76% and 77%.
• Cash, cash equivalents, and short-term investments stood at $60.0 million as of September 30, 2025.

Sentiment

Score: 8

Explanation: The company reported strong financial results with significant revenue growth and improved gross margins. The upward revision of full-year guidance for both revenue and gross margin indicates positive momentum and management confidence. Strategic advancements in product development and regulatory submissions further contribute to a positive outlook, despite continued operating losses and a slight decrease in cash reserves.

Positives

• Record quarterly revenue of $27.4 million in Q3 2025, a 30% increase year-over-year.
• RNS System revenue grew 31% to $22.6 million in Q3 2025.
• Strong gross margin of 77.4% in Q3 2025, an improvement from 73.2% in Q3 2024, driven by positive product mix and manufacturing efficiencies.
• Loss from operations improved to ($2.6) million in Q3 2025 from ($4.2) million in Q3 2024.
• Net loss improved to ($3.5) million in Q3 2025 from ($5.5) million in Q3 2024.
• Increased full-year 2025 revenue guidance to $97 million $98 million (previously $94 million $98 million).
• Increased full-year 2025 gross margin guidance to 76% 77% (previously 75% 76%).
• Achieved record highs in active accounts, prescribers, and utilization.
• Submitted Seizure ID, the first of a suite of planned NeuroPace AI applications, to the FDA for approval.

Negatives

• Total operating expenses increased to $23.8 million in Q3 2025 from $19.7 million in Q3 2024, driven by scaling commercial activities, direct-to-consumer marketing, R&D for next-gen platform and AI tools, and personnel-related expenses.
• Cash, cash equivalents, and short-term investments decreased to $60.0 million as of September 30, 2025, from $62.1 million at the end of the prior quarter.
• The company continues to operate at a net loss of ($3.5) million for the quarter.

Risks

• Actual operating results may differ significantly from any guidance provided.
• Uncertainties related to market acceptance and adoption of the RNS System and impacts to revenue for 2025 and in the future.
• Risks to future revenue growth as a result of the expiration of the DIXI distribution agreement on September 30, 2025.
• Operating expenses could be higher than anticipated and cash resources could be used sooner than expected.
• Gross margin may be lower than forecast.
• Risks related to the pricing of the RNS System and availability of adequate reimbursement for implantation procedures and for clinicians to provide ongoing care for patients treated with the RNS System.
• Risks related to regulatory compliance and expectations for regulatory submissions and approvals to expand the market for the RNS System, including risks related to the NAUTILUS clinical trial.
• Risks related to product development, including risks related to the development of AI-powered software, including NeuroPace AI and Seizure ID, and the next-generation device platform.
• Risks related to reliance on contractors and other third parties, including single-source suppliers and vendors.

Future Outlook

NeuroPace expects continued strong revenue growth for the full year 2025, with updated guidance of $97 million to $98 million, and an improved gross margin of 76% to 77%. The company remains on track to submit the NAUTILUS PMA Supplement to the FDA for IGE indication expansion by year-end 2025 and is advancing its AI-enabled tools, including Seizure ID, and a next-generation platform, aiming to establish the RNS System as the standard of care in drug-resistant epilepsy.

Management Comments

• Our strong third-quarter performance reflects the continued execution of our strategy and the momentum across our business being driven by our team.
• We delivered record revenue growth with strong gross margin, operating and cash discipline while advancing key clinical and product development initiatives that reinforce our leadership in personalized neuromodulation.
• Our decision to strategically focus our organizational efforts on our differentiated RNS System is reflected in our third quarter results, and with growing awareness of RNS therapy and an expanding base of prescribers, we are encouraged by the progress we are making toward establishing the RNS System as the standard of care in drug-resistant epilepsy.

Industry Context

NeuroPace operates in the medical device sector, specifically focusing on neuromodulation for epilepsy. The company's RNS System is positioned as a novel, brain-responsive platform, aiming to set a new standard of care for drug-resistant epilepsy. The development of AI-enabled tools like Seizure ID aligns with broader industry trends towards integrating artificial intelligence into medical diagnostics and treatment to improve clinical outcomes and operational efficiency. The pursuit of an IGE indication expansion for the RNS System could significantly broaden its market reach within the epilepsy treatment landscape.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved gross margins, and increased full-year guidance, potentially leading to increased share value.
• Patients: Potential for improved outcomes and broader access to RNS therapy with the IGE indication expansion and new AI-enabled tools like Seizure ID.
• Employees: Increased sales and marketing, and R&D expenses suggest continued investment in personnel and growth opportunities.
• Customers (Healthcare Providers): Record highs in active accounts and prescribers indicate growing adoption and utilization of the RNS System.
• Creditors: Long-term borrowings of $58.7 million are noted, with cash reserves of $60.0 million providing liquidity.

Next Steps

• Submit NAUTILUS PMA Supplement to FDA for IGE indication expansion by year-end 2025.
• Continue development of a next-generation platform and AI-enabled tools.
• Advance Project CARE momentum.
• Host a conference call on November 4, 2025, to discuss Q3 2025 financial results.

Key Dates

Recommendation

The company demonstrates strong operational execution with record revenue growth and significant improvement in gross margins. The upward revision of full-year guidance for both revenue and gross margin signals robust business momentum and management's confidence in future performance. Strategic initiatives, including the FDA submission for IGE expansion and AI product development, position the company for continued market penetration and innovation. While the company still reports a net loss and increased operating expenses, these are largely investments in growth and R&D, which are critical for long-term value creation in a medical device company. The positive financial and operational trajectory, coupled with expanding market opportunities, makes this an attractive investment.

Keywords

NeuroPace, NPCE, Epilepsy, RNS System, Neuromodulation, Medical Device, Financial Results, Revenue Guidance, Gross Margin, FDA Submission, Seizure ID, AI, Idiopathic Generalized Epilepsy, IGE, NAUTILUS study, Drug-Resistant Epilepsy